Browse Health
Surgical Specialist, Orthopaedic Surgeon
13 years of experience
Accepting new patients
Video profile


Education ?

Medical School Score
George Washington University (1999)
Thomas Jefferson University Hospital (2005) *
University of Southern California (2006) *
* This information was reported to Vitals by the doctor or doctor's office.

Awards & Distinctions ?

Patients' Choice 5th Anniversary Award (2013)
Patients' Choice Award (2009 - 2015)
Compassionate Doctor Recognition (2011 - 2013, 2015)
On-Time Doctor Award (2014 - 2015)
University of Southern California School of Medicine
Clinical Instructor
Associations (knee Osteoarthritis)-

Affiliations ?

Dr. Fletcher is affiliated with 1 hospitals.

Hospital Affiliations

  • Norwalk Hospital
    34 Maple St, Norwalk, CT 06850
  • Publications & Research

    Dr. Fletcher has contributed to 6 publications.
    Title Copd Uncovered: an International Survey on the Impact of Chronic Obstructive Pulmonary Disease [copd] on a Working Age Population.
    Date December 2011
    Journal Bmc Public Health

    Approximately 210 million people are estimated to have chronic obstructive pulmonary disease [COPD] worldwide. The burden of disease is known to be high, though less is known about those of a younger age. The aim of this study was to investigate the wider personal, economic and societal burden of COPD on a cross country working-age cohort.

    Title Treatment of Rheumatoid Arthritis with Oral Type Ii Collagen. Results of a Multicenter, Double-blind, Placebo-controlled Trial.
    Date March 1998
    Journal Arthritis and Rheumatism

    OBJECTIVE: Oral administration of cartilage-derived type II collagen (CII) has been shown to ameliorate arthritis in animal models of joint inflammation, and preliminary studies have suggested that this novel therapy is clinically beneficial and safe in patients with rheumatoid arthritis (RA). The present study was undertaken to test the safety and efficacy of 4 different dosages of orally administered CII in patients with RA. METHODS: Two hundred seventy-four patients with active RA were enrolled at 6 different sites and randomized to receive placebo or 1 of 4 dosages (20, 100, 500, or 2,500 microg/day) of oral CII for 24 weeks. Efficacy parameters were assessed monthly. Cumulative response rates (percentage of patients meeting the criteria for response at any time during the study) were analyzed utilizing 3 sets of composite criteria: the Paulus criteria, the American College of Rheumatology criteria for improvement in RA, and a requirement for > or = 30% reduction in both swollen and tender joint counts. RESULTS: Eighty-three percent of patients completed 24 weeks of treatment. Numeric trends in favor of the 20 microg/day treatment group were seen with all 3 cumulative composite measures. However, a statistically significant increase (P = 0.035) in response rate for the 20 microg/day group versus placebo was detected using only the Paulus criteria. The presence of serum antibodies to CII at baseline was significantly associated with an increased likelihood of responding to treatment. No treatment-related adverse events were detected. The efficacy seen with the lowest dosage is consistent with the findings of animal studies and with known mechanisms of oral tolerance in which lower doses of orally administered autoantigens preferentially induce disease-suppressing regulatory cells. CONCLUSION: Positive effects were observed with CII at the lowest dosage tested, and the presence of serum antibodies to CII at baseline may predict response to therapy. No side effects were associated with this novel therapeutic agent. Further controlled studies are required to assess the efficacy of this treatment approach.

    Title Study of Lithium Absorption by Users of Spas Treated with Lithium Ion.
    Date August 1994
    Journal Human & Experimental Toxicology

    This study examines the possible dermal absorption of lithium ion into the blood serum of spa/hot tub bathers. Fifty-three participants (28 males and 25 females) spent 20 minutes per day, 4 days per week for 2 consecutive weeks in one of two assigned spas. The participants were randomly assigned to one of the two spas after matching based on sex, age, and use of oral contraceptives. The test spa contained 40 +/- 5 ppm lithium ion, while the control spa contained no additional lithium ion above the background levels of approximately 0.02 ppm. The exposure in the spa treated with lithium ion (from lithium chloride) simulated the maximum exposure that would be expected in a spa sanitized with lithium hypochlorite. The two spas were maintained at 101 +/- 2 degrees F. Serum lithium ion levels before and after spa use were determined using graphite-furnace atomic absorption spectroscopy with a minimum detectable level of lithium ion in serum of 2 micrograms l-1 (ppb). There was no statistically significant difference in serum lithium levels between the control and treatment group at any stage. We conclude that dermal exposure to lithium ion (as would be present after treatment of a spa with lithium hypochlorite) did not result in a detectable increase in the serum lithium ion level.

    Title Serum and Tissue Calcium in Human Breast Carcinoma.
    Date August 1970
    Journal Cancer Research
    Title Serum and Tissue Magnesium Levels in Human Breast Carcinoma.
    Date May 1970
    Journal The Journal of Surgical Research
    Title Endotoxin-free Biologically Active Component of Escherichia Coli.
    Date July 1969
    Journal Journal of Bacteriology

    The proteinaceous component of gram-negative bacteria, which has been termed "protodyne," enhances nonspecific host resistance while eliciting a slight pyrogenic response equivalent to 0.2% that of a typical endotoxin. Since this material still contains small amounts of carbohydrate and lipid, it was imperative to establish that its biological activities are not the result of endotoxin contamination. Evidence that the protective activity of protodyne does not result from endotoxin contamination has now been obtained by an evaluation of the Pronase digestion products of this substance. These digestion products were found to be nonpyrogenic and to contain no measurable amount of 2-keto-3-deoxyoctonate, an essential component of bacterial lipopolysaccharides.

    Similar doctors nearby

    Dr. Jeffrey Deluca

    Orthopaedic Surgery
    Norwalk, CT

    Dr. Michael Soojian

    Orthopaedic Surgery
    11 years experience
    Norwalk, CT

    Dr. Paul Markey

    Orthopaedic Surgery
    43 years experience
    Norwalk, CT

    Dr. Michael Lynch

    Orthopaedic Surgery
    28 years experience
    Norwalk, CT

    Dr. Sheldon Greenberg

    38 years experience
    Norwalk, CT

    Dr. Robert Brady

    Orthopaedic Surgery
    13 years experience
    Norwalk, CT
    Search All Similar Doctors